Attached files
| file | filename |
|---|---|
| EX-99.1 - PHARMACYCLICS INC | ex991to8k07380_04152010.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 15, 2010
|
PHARMACYCLICS, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
000-26658
|
94-3148201
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
995 E. Arques Avenue, Sunnyvale, California
|
4085-4521
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (408) 774-0330
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01.
|
Other Events.
|
On April 15, 2010, Pharmacyclics, Inc., a Delaware corporation (the “Registrant”), announced that it will present at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 in Washington, DC.
In the announcement, Dr. Joseph J. Buggy, the Registrant’s Vice President of Research stated that, “while the Btk inhibitor PCI-32765 continues to show promise in clinical trials in patients with B cell lymphomas and leukemias, we are now seeing preclinical evidence that the compound may also be efficacious in mast cell-driven cancers, which include certain pancreatic tumors and melanomas. In addition, our HDAC inhibitor PCI-24781 is now showing synergy with bortezomib in several indications. Based on this discovery, and our previous work, we are planning Phase I/II trials with PCI -24781 in combination with a number of other chemotherapeutics in collaboration with our ex-US global partner, Les Laboratories Servier.”
The foregoing description is qualified in its entirety by reference to the Registrant's Press Release dated April 15, 2010, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release of Pharmacyclics, Inc. dated April 15, 2010.
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
April 15, 2010
|
PHARMACYCLICS, INC.
|
|
|
By:
|
/s/ Rainer M. Erdtmann |
|
Name: Rainer M. Erdtmann
|
|
|
Title: Vice President, Finance & Administration and Secretary
|
|
3